# Effectiveness of Per-Operative Bupivicaine in Reducing Postoperative Pain at Port Site and Improving Mobility in Knee Arthoscopic Procedures

> **NCT07090928** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Khyber Teaching Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Arthroscopic Surgery

## Interventions

- **DRUG:** 5 ml of 0.5% bupivacaine infiltrated at each port site
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07090928
- **Lead sponsor:** Khyber Teaching Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07090928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07090928, "Effectiveness of Per-Operative Bupivicaine in Reducing Postoperative Pain at Port Site and Improving Mobility in Knee Arthoscopic Procedures". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07090928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*